Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 18'th Oct 2024
NOVATO, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
RARE's Bone Disorder Drug Gets FDA's Breakthrough Therapy Tag
12:10pm, Tuesday, 08'th Oct 2024
Ultragenyx announces that the FDA grants Breakthrough Therapy designation to its investigational osteogenesis imperfecta treatment candidate, setrusumab.
RARE's Wilson Disease Candidate Betters Standard Therapy in Study
12:05pm, Friday, 04'th Oct 2024
Ultragenyx reports superior efficacy of UX701 for Wilson disease compared with standard therapy from the Stage 1 cohorts of its pivotal phase I/II/III study.
NOVATO, Calif., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today reported that the Phase 1/2/3 Cyprus 2+ study of its UX701 gene therapy has demonstrated meaningfu
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
08:00am, Thursday, 26'th Sep 2024
NOVATO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will present seven abstracts related to its ongoing late-stage program evaluati
AMGEN TO HOST CONFERENCE CALL TO DISCUSS NEW TOPLINE DATA IN INFLAMMATION AND RARE DISEASE
04:00pm, Monday, 23'rd Sep 2024
THOUSAND OAKS, Calif. , Sept. 23, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcasted call for the investment community at 1:30 p.m.
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Wednesday, 18'th Sep 2024
NOVATO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ra
Ultragenyx to Participate in Investor Conferences in September
04:30pm, Thursday, 29'th Aug 2024
Morgan Stanley 22 nd Annual Global Healthcare Conference on September 4 Cantor Global Healthcare Conference on September 17 Bank of America Global Healthcare Conference on September 18 NOVATO, Calif.,
Ultragenyx's Strong Pipeline And Valuation Concerns: A Balanced Perspective
10:22am, Thursday, 22'nd Aug 2024
Ultragenyx develops therapies for rare genetic diseases, with a portfolio including Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company's promising pipeline targets severe diseases like osteogenesis
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 21'st Aug 2024
NOVATO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
3 Genomics Stocks That May Transform Personalized Medicine
10:45am, Tuesday, 06'th Aug 2024
When the human genome was fully sequenced in 2003, the prospects of genetic medicine ushered in a new era of human health. Today, scientists and drug developers have a better understanding of the gene
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2024 Earnings Call Transcript
06:07pm, Friday, 02'nd Aug 2024
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q2 2024 Earnings Conference Call August 1, 2024 5:00 PM ET Company Participants Joshua Higa - Vice President, Investor Relations Emil Kakkis - Chief Execu
Ultragenyx (RARE) Q2 Loss Narrower Than Expected, Revenues Up
08:46am, Friday, 02'nd Aug 2024
Ultragenyx (RARE) reports encouraging second-quarter 2024 results, beating both earnings and revenue estimates driven by the year-over-year increase of Crysvita and Dojolvi sales.
Amlogenyx Inc. Closes Successful Seed Funding Led by GordonMD® Global Investments LP
08:15am, Friday, 02'nd Aug 2024
BEVERLY HILLS, Calif.--(BUSINESS WIRE)--GordonMD® Global Investments LP announced today that Amlogenyx Inc. has completed a seed funding round of USD 14 million. Amlogenyx, a subsidiary of Ultragenyx
Compared to Estimates, Ultragenyx (RARE) Q2 Earnings: A Look at Key Metrics
08:00pm, Thursday, 01'st Aug 2024
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Stree
